BioCryst Pharma (BCRX) Granted Orphan Drug and Fast Track Status from the FDA

BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) announced that the FDA has granted Fast Track designation for BCX4161, a novel, orally administered, selective inhibitor of plasma kallikrein in advanced clinical development for the treatment of hereditary angioedema. The Fast Track designation process of the FDA is designed to facilitate the development and expedite the review and approval of […] View the full post at: BioCryst Pharma (BCRX) Granted Orphan Drug and Fast Track Status from the FDA Related posts: Unintended Consequences of Swine Flu Panic